---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-051251"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2026-07-31T12:48:17+00:00"
generated_at: "2026-07-31T12:50:05.066112+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Vistagen appoints Douglas J. Williamson, M.D. to Board of Directors

## Summary
- Dr. Williamson appointed to Vistagen's Board effective July 29, 2026.
- He received options to purchase 40,826 shares at $0.2433, vesting over three years.
- Williamson brings 30 years of neuroscience drug development and regulatory experience.
- He previously served as CMO of QurAlis, EVP R&D at Acadia, and senior roles at Lundbeck and Eli Lilly.
- He will serve until the next annual meeting or until successor is elected.

## SEC filing metadata
- accession: 0001628280-26-051251
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2026-07-31T12:48:17+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828026051251/0001628280-26-051251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828026051251/vtgn-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-051251
- JSON: https://secwatch.observer/filing/0001628280-26-051251.json
- Plain text: https://secwatch.observer/filing/0001628280-26-051251.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.